RVL Pharmaceuticals plc (NASDAQ: RVLP ) announced preliminary Q2 FY22 sales from Upneeq of $8.4 million , up 42% sequentially.
Upneeq (oxymetazoline hydrochloride ophthalmic solution) is an approved ophthalmic solution for blepharoptosis or droopy eyelids.
The company also announced that from ... Full story available on Benzinga.com